Clinuvel Pharmaceuticals (CLVLF) files ASX notice on cessation of securities

Q: What does Clinuvel Pharmaceuticals (CLVLF) report in this July 2026 Form 6-K?

Clinuvel reports that it filed an ASX announcement titled “Appendix 3H - Notification of cessation of securities” on July 27, 2026, and makes that announcement available to U.S. investors as Exhibit 99.1 to this Form 6-K.

Q: What is Exhibit 99.1 in Clinuvel Pharmaceuticals (CLVLF) July 2026 Form 6-K?

Exhibit 99.1 is an ASX announcement by Clinuvel dated July 27, 2026 titled “Appendix 3H - Notification of cessation of securities” . The Form 6-K forwards this announcement to the U.S. market without adding further transaction details.

Q: Which stock exchange filing does Clinuvel (CLVLF) reference in this Form 6-K?

Clinuvel references an announcement filed with the Australian Securities Exchange (ASX) . The Form 6-K states that the company lodged an ASX announcement called “Appendix 3H - Notification of cessation of securities” and attaches it as Exhibit 99.1.

Q: Does Clinuvel Pharmaceuticals (CLVLF) describe the specific securities ceasing in this Form 6-K?

The Form 6-K only notes an ASX announcement titled “Notification of cessation of securities” and attaches it as Exhibit 99.1. It does not describe within the text which specific securities or quantities are affected.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

Clinuvel Pharmaceuticals Limited, a foreign private issuer, submitted a Form 6-K for July 2026 stating that it had lodged with the Australian Securities Exchange an announcement titled “Appendix 3H - Notification of cessation of securities,” which is included as Exhibit 99.1 for U.S. investors.

Key Terms

foreign private issuer, Form 6-K, Appendix 3H - Notification of cessation of securities

3 terms

foreign private issuer regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Form 6-K regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

Appendix 3H - Notification of cessation of securities regulatory

"an announcement captioned “Appendix 3H - Notification of cessation of securities”"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/27/2026 - 02:22 PM Accepted by SEC EDGAR 07/27/2026 - 02:22 PM

FAQ

What does Clinuvel Pharmaceuticals (CLVLF) report in this July 2026 Form 6-K?

Clinuvel reports that it filed an ASX announcement titled “Appendix 3H - Notification of cessation of securities” on July 27, 2026, and makes that announcement available to U.S. investors as Exhibit 99.1 to this Form 6-K.

What is Exhibit 99.1 in Clinuvel Pharmaceuticals (CLVLF) July 2026 Form 6-K?

Exhibit 99.1 is an ASX announcement by Clinuvel dated July 27, 2026 titled “Appendix 3H - Notification of cessation of securities”. The Form 6-K forwards this announcement to the U.S. market without adding further transaction details.

Which stock exchange filing does Clinuvel (CLVLF) reference in this Form 6-K?

Clinuvel references an announcement filed with the Australian Securities Exchange (ASX). The Form 6-K states that the company lodged an ASX announcement called “Appendix 3H - Notification of cessation of securities” and attaches it as Exhibit 99.1.

Who signed Clinuvel Pharmaceuticals (CLVLF) July 27, 2026 Form 6-K?

The Form 6-K was signed on behalf of Clinuvel Pharmaceuticals Limited by Philippe Wolgen, who is identified as Managing Director and Chief Executive Officer, providing officer-level authorization for the furnished information.

Does Clinuvel Pharmaceuticals (CLVLF) describe the specific securities ceasing in this Form 6-K?

The Form 6-K only notes an ASX announcement titled “Notification of cessation of securities” and attaches it as Exhibit 99.1. It does not describe within the text which specific securities or quantities are affected.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number: 001-43353

CLINUVEL PHARMACEUTICALS LIMITED

Level 22, 535 Bourke Street

Melbourne, VIC 3000

Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On July 27, 2026, Clinuvel Pharmaceuticals Limited filed with the Australian Securities Exchange an announcement captioned “Appendix 3H - Notification of cessation of securities”, a copy of which announcement is attached to this Form 6-K as Exhibit 99.1.

Exhibits

Exhibit No.		Description

99.1		Announcement dated July 27, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CLINUVEL PHARMACEUTICALS LIMITED

Date: July 27, 2026	By:	/s/ Philippe Wolgen
	Name:	Philippe Wolgen
	Title:	Managing Director and Chief Executive Officer